

ImmunoGuide®

Instructions for Use

Certolizumab pegol ELISA (mAb-based)

Enzyme immunoassay for the specific and quantitative determination
of free Certolizumab pegol in serum and plasma

REF: IG-AB109



12X8



2-8°C



AYBAYTECH Biyoteknoloji Ltd. Sti.
Macun Mah. Batı Blv. ATB İş Merkezi No: 1/285,
06374-Yenimahalle, Turkey
Tel : +90 312 397 88 05
Fax : +90 312 397 88 06
e-mail: info@aybaytech.com
www.aybaytech.com

<u>Contents</u>	<u>Page</u>
1. Intended Use	2
2. Summary and Explanation	2
3. Principle of the Test	2
4. Warnings and Precautions	3
5. Storage and Stability of the Kit	3
6. Specimen Collection, Handling and Storage	3
7. Contents of the Kit	4
8. Materials Required but not Supplied	4
9. Procedure Notes	5
10. Pre-Test Setup Instructions	5
10.1. Preparation of Components	5
10.2. Dilution of Samples	5
11. Test Procedure	6
11.1. General Remarks	6
11.2. Assay Procedure	7
11.3. Quality Control	8
11.4. Calculation of Results	8
12. Assay characteristics	9
12.1. Specificity	9
12.2. Sensitivity	10
12.3. Precision	10
12.4. Recovery	10
13. Automation	10
14. References	10

1. INTENDED USE

Enzyme immunoassay for the specific and quantitative determination of free Certolizumab pegol in serum and plasma.

2. SUMMARY AND EXPLANATION

The drug Certolizumab pegol (trade name Cimzia[®]) is a tumor necrosis factor alpha (TNF- α) blocker and binds to human TNF- α with a KD of 90pM. Certolizumab pegol is a recombinant, humanized antibody Fab' fragment, with specificity for TNF- α , conjugated to an approximately 40kDa polyethylene glycol (PEG2MAL40K). The Fab' fragment is manufactured in *E. coli* and is subsequently subjected to purification and conjugation to PEG2MAL40K, to generate Certolizumab pegol.

The *ImmunoGuide* Certolizumab pegol ELISA (mAb-based) kit can be efficiently used for measuring free Certolizumab pegol levels in serum and plasma.

3. PRINCIPLE OF THE TEST

This ELISA is based on Certolizumab pegol-specific mouse monoclonal antibody (catcher Ab, *ImmunoGuide* clone CY). Standards and diluted samples are incubated in the microtiter plate coated with IG-CY mAb. After incubation, the wells are washed. A biotinylated recombinant human tumor necrosis factor alpha (rhTNF- α) is added and binds to the Fab part of Certolizumab pegol. Following incubation, wells are washed and the horseradish peroxidase (HRP)-conjugated streptavidin is added and binds to the biotinylated rhTNF- α . Following incubation, wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of Certolizumab pegol in the sample or standard. Results of samples can be determined by using the standard curve. Preincubation of Certolizumab pegol with rhTNF- α inhibited the reaction in a concentration dependent manner. Therefore, the *ImmunoGuide* Certolizumab pegol ELISA (mAb-based) measures the free form of Certolizumab pegol.

4. WARNINGS AND PRECAUTIONS

1. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.
2. In case of severe damage of the kit package, please contact **AybayTech** or your supplier in writing, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
3. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
4. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
5. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.
6. Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guidelines or regulations.
7. Avoid contact with Stop solution. It may cause skin irritations and burns.
8. If any component of this kit contains human serum or plasma it is indicated and if so, it have been tested and were found to be negative for HIV I/II, HBsAg and HCV. However, the presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.
9. Some reagents contain preservatives. In case of contact with eyes or skin, flush immediately with water.

5. STORAGE AND STABILITY OF THE KIT

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.

6. SPECIMEN COLLECTION, HANDLING AND STORAGE Serum, Plasma (EDTA, Heparin)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage:	2-8°C	≤-20°C (Aliquots)	Keep away from heat or direct sun light Avoid repeated freeze-thaw cycles
Stability:	3 d	6 mon	

7. CONTENTS OF THE KIT

QUANTITY	COMPONENT
1 x 12 x 8	Microtiter Plate Break apart strips coated with anti-Certolizumab pegol monoclonal antibody.
5 x 0.5 mL	Certolizumab pegol Standards A-E , Concentrate (10X) 2000; 600; 200; 60; and 0 µg/mL Used for construction of the standard curve. Contains Certolizumab pegol, proteins, preservative and stabilizer.
1 x 12 mL	Assay Buffer Blue colored. Ready to use. Contains proteins and preservative.
1 x 60 mL	Dilution Buffer , Concentrate (5X) Contains orange dye, proteins and preservative.
1 x 12 mL	Biotinylated TNF-α Green colored. Ready to use. Contains biotinylated recombinant human tumor necrosis factor alpha (rhTNFα), proteins, stabilizers and <15 mM NaN ₃ .
1 x 12 mL	Enzyme Conjugate Red colored. Ready to use. Contains horseradish peroxidase(HRP)-conjugated streptavidin (HRP-Streptavidin), Proclin [®] and stabilizers.
1 x 12 mL	TMB Substrate Solution Ready to use. Contains 3,3',5,5'-Tetramethylbenzidine (TMB).
1 x 12 mL	Stop Solution Ready to use. 1 N Hydrochloric acid (HCl).
1 x 50 mL	Wash Buffer , Concentrate (20x) Contains buffer, Tween [®] 20 and Kathon [™] .
3 x 1	Adhesive Seal For sealing microtiter plate during incubation.

8. MATERIALS REQUIRED BUT NOT SUPPLIED

1. Micropipettes (< 3% CV) and tips to deliver 5-1000 µL.
2. Bidistilled or deionised water and calibrated glasswares (e.g. flasks or cylinders).
3. Wash bottle, automated or semi-automated microtiter plate washing system.
4. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength at 600-650 nm is optional).
5. Absorbent paper towels, standard laboratory glass or plastic vials, and a timer.

9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared readily at the appropriate time. Allow all reagents and specimens to reach room temperature (20-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange the caps of vials. Always cap not used vials. Do not reuse wells or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
7. Humidity affects the coated wells. Do not open the pouch until it reaches room temperature. Unused wells should be returned immediately to the resealed pouch including the desiccant

10. PRE-TEST SETUP INSTRUCTIONS

10.1. Preparation of Components*


Dilute/ dissolve	Component		Diluent	Relation	Remarks	Storage	Stability
10 mL	Wash Buffer	up to 200 mL	Distilled Water	1:20	Warm up at 37°C to dissolve crystals. Mix vigorously.	2-8 °C	4 w
10 mL	Dilution Buffer	up to 50 mL	Distilled Water	1:5		2-8 °C	4 w

* Prepare Wash and Dilution Buffers before starting the assay procedure.

10.2. Dilution of Standards and Samples

The dilutions depicted below are examples of how to obtain final 1:500 dilution. Standards and samples should be properly diluted as homogenous mixture before starting the assay procedure. It is recommended mixing the standards and samples well to homogenous solution at each dilution step. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

1. 20 μL of standard added to 180 μL of 1X dilution buffer, giving the total volume of 200 μL and a dilution of 1:10.
2. 10 μL of sample added to 90 μL of 1X dilution buffer, giving the total volume of 100 μL and a dilution of 1:10.
3. 10 μL of 1:10 diluted sample added to 490 μL of 1X dilution buffer, giving the total volume of 500 μL and a dilution of 1:500. This second dilution should not be done with the standards.
4. Samples with a drug concentration above the measuring range should be rated as ">highest standard". The result should not be extrapolated. The sample in question should be further diluted with 1X Dilution Buffer and then retested.



11. TEST PROCEDURE

11.1. GENERAL REMARKS

11.1.1. Before performing the assay, samples and assay kit should be brought to room temperature (about 30 minutes beforehand) and ensure the homogeneity of the solution.

11.1.2. All Standards should be run with each series of unknown samples.

11.1.3. Standards should be subject to the same manipulations and incubation times as the samples being tested.

11.1.4. All steps of the test should be completed without interruption.

11.1.5. Use new disposable plastic pipette tips for each reagent, standard or specimen in order to avoid cross contamination.

11.1.6. The total pipetting time needed for dispensing all samples into the wells should not exceed 5 minutes. If this is difficult to achieve the samples should be pre-dispensed in a separate neutral polypropylene microplate and then transferred into the reaction ELISA plate by a multi channel pipette.

11.2. ASSAY PROCEDURE

1.	Pipette 100 µL of Assay Buffer into each of the wells to be used.
2.	Pipette 50 µL of each 1:10 Diluted Standard, and 1:500 Diluted Samples into the respective wells of the microtiter plate. Bubble formation during the pipetting of standards and samples must be avoided. <u>Wells</u> A1: Standard A B1: Standard B C1: Standard C D1: Standard D E1: Standard E F1 and so on: Diluted samples (Serum/Plasma)
3.	Cover the plate with adhesive seal. Shake plate carefully by tapping several times. Incubate the plate on a bench top for 60 min at room temperature (RT, 20-25°C).
4.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 5 X 350 µL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
5.	Pipette 100 µL of Biotinylated TNF into each well.
6.	Cover the plate with adhesive seal. Shake plate carefully by tapping several times. Incubate the plate on a bench top for 60 min at room temperature (RT, 20-25°C).
7.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 5 X 350 µL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
8.	Pipette 100 µL of Enzyme Conjugate (HRP-Streptavidin) into each well.
9.	Cover plate with adhesive seal. Shake plate carefully. Incubate 30 min at RT.
10.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 5 X 350 µL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
11.	Pipette 100 µL of Ready-to-Use TMB Substrate Solution into each well.
12.	Incubate 10 min at RT. Avoid exposure to direct sunlight.
13.	Stop the substrate reaction by adding 100 µL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow.
14.	Measure optical density (OD) with a photometer at 450 nm (Reference at OD620 nm is optional) within 15 min after pipetting the Stop Solution.

11. 3. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards/controls must be found within the acceptable ranges as stated above and/or label. If the criteria are not met, the run is not valid and should be repeated. In case of any deviation, the following technical issues should be reviewed: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

11. 4. CALCULATION OF RESULTS

A standard curve should be constructed using the standard concentration (X-axis) versus the OD450 (or OD450/620) values (Y-axis). This can be done manually using graph paper or with a computer program. Concerning the data regression by computer, it is recommended to primarily use the "4 Parameter Logistic (4PL)" or alternatively the "point-to-point calculation". In case of manual plot there are 2 options: Semilog graph (see Fig. A) or linear graph (see Fig. B). Semilog graph paper is available at <http://www.papersnake.com/logarithmic/semilogarithmic/>.


The concentration of the samples can be read from this standard curve as follows. Using the absorbance value for each sample, determine the corresponding concentration of the drug from the standard curve. This value always has to be **multiplied by the individual dilution factor, which usually will be 500**. If any diluted sample is reading greater than the highest standard, it should be further diluted appropriately with 1X Dilution Buffer and retested. Also this second dilution has to be used for calculation of the final result. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

In order to measure lower levels (0,1-3 µg/mL) of Certolizumab pegol in a sample, this serum/plasma sample should only be diluted at 1:50 with 1X Dilution Buffer and then tested. This time the result, obtained from the standard curve by plotting the OD value of sample, should be multiplied only by 50 to get the target drug level in the undiluted sample.

Typical Calibration Curve

(Just an example. Do not use it for calculation!)

1:10 Diluted Standard	A	B	C	D	E
Concentration (ng/mL)	200	60	20	6	0
Mean OD _{450/620 nm}	3.110	1.233	0.470	0.151	0.022



12. ASSAY CHARACTERISTICS

12.1. SPECIFICITY

There is no cross reaction with any other proteins present in native human serum. A screening test was performed with 48 different native human sera at a dilution of 1:500. All produced OD_{450/620 nm} values (ranged from 0.018 to 0.022) less than the mean OD (0.151) of the diluted standard D (6 ng/mL). In addition, binding of Certolizumab pegol is inhibited by recombinant human tumor necrosis factor alpha (rhTNF α) in a concentration dependent manner. Therefore, the *ImmunoGuide* Certolizumab pegol ELISA (mAb-based) measures the biologically active free form of Certolizumab pegol, i.e. not pre-occupied by TNF α . No cross reaction was observed with sera spiked with the other therapeutic antibodies including Infliximab, Etanercept, Adalimumab, Golimumab, Remsima, Tocilizumab, Trastuzumab and Rituximab tested at concentration of 100 μ g/mL. All produced mean OD_{450/620 nm} values less than 0.040.

12.2. SENSITIVITY

The lowest detectable concentration level in the well that can be clearly distinguished from the zero standard is 2 ng/mL (zero standard +2SD read from the curve) under the above-described conditions. Analytical sensitivity is 2 ng/mL, and corresponding to the detection limit (limit of quantification) of 1 µg/mL for undiluted clinical samples because the serum or plasma samples are instructed to be diluted at 1:500 before starting the assay.

12.3. PRECISION

Intra-assay CV: <10%.

Inter-assay CV: <10%.

12.4. RECOVERY

Recovery rate was found to be >95% with native human serum and plasma samples when spiked with exogenous Certolizumab pegol at 100, 30, 10 and 3 µg/mL.

13. AUTOMATION

The *ImmunoGuide* Certolizumab pegol ELISA (mAb-based) is suitable also for being used by an automated ELISA processor.

14. REFERENCES

1. Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. *J Clin Pharmacol.* 2015; 55 Suppl 3: S39-50.
2. Derer S, Till A, Haesler R, Sina C, Grabe N, Jung S, Nikolaus S, Kuehbacher T, Groetzinger J, Rose-John S, Rosenstiel PC, Schreiber S. mTNF reverse signalling induced by TNF α antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease. *Gut.* 2013; 62(3): 376-86.
3. Molinelli E, Campanati A, Ganzetti G, Offidani A. Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts. *Curr Drug Saf.* 2016; 11(1): 35-43.
4. Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. *Therap Adv Gastroenterol.* 2013; 6(4): 269-93.
5. Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A; BRAGGSS. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. *Ann Rheum Dis.* 2016 May 31. pii: annrheumdis-2015-208849. doi: 10.1136/annrheumdis-2015-208849.
6. Shu Q, Amin MA, Ruth JH, Campbell PL, Koch AE. Suppression of endothelial cell activity by inhibition of TNF α . *Arthritis Res Ther.* 2012; 14(2): R88.
7. Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages. *Gastroenterology.* 2011; 141(6): 2026-38.

8. Nielsen OH, Bjerrum JT, Seidelin JB, Nyberg C, Ainsworth M. Biological treatment of Crohn's disease. *Dig Dis*. 2012; 30 Suppl 3: 121-33.
9. Loftus EV Jr, Colombel JF, Schreiber S, Randall CW, Regueiro M, Ali T, Arendt C, Coarse J, Spearman M, Kosutic G. Safety of Long-Term Treatment With Certolizumab Pegol in Patients with Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials. *Clin Gastroenterol Hepatol*. 2016 Jul 24. pii: S1542-3565(16)30440-2. doi: 10.1016/j.cgh.2016.07.019.
10. Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECISE 4 Study. *Inflamm Bowel Dis*. 2016; 22(8): 1870-80.
11. Cassinotti A, Ardizzone S, Porro GB. Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. *Core Evid*. 2008; 2(3): 209-29.
12. Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, Nesbitt A. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. *J Reprod Immunol*. 2016; 116: 7-12.
13. Lee YH, Bae SC. Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis : Meta-analysis of randomized controlled trials. *Z Rheumatol* 2016 Jun 16. DOI10.1007/s00393-016-0133-z
14. Rudwaleit M, Rosenbaum JT, Landewé R, Marzo-Ortega H, Sieper J, van der Heijde D, Davies O, Bartz H, Hoepken B, Nurminen T, Deodhar A. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. *Arthritis Care Res (Hoboken)*. 2016; 68(6): 838-44.
15. Pope J, Bingham CO 3rd, Fleischmann RM, Dougados M, Massarotti EM, Wollenhaupt J, Duncan B, Coteur G, Weinblatt ME. Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. *Arthritis Res Ther*. 2015; 17: 343.
16. Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TW, Cutolo M, van der Heijde D, Duncan B, Davies O, Luijckens K, Dougados M. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. *Arthritis Res Ther*. 2015; 17(1): 325.
17. Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewé R, de Longueville M, Hoepken B, Peterson L, van der Heijde D. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. *RMD Open*. 2015 Jun 25;1(1):e000119. doi: 10.1136/rmdopen-2015-000119. eCollection 2015
18. Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Kobayashi M, Shoji T, Togo O, Miyasaka N, Koike T. Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. *Mod Rheumatol*. 2016; 26(4): 473-80.
19. Capogrosso Sansone A, Mantarro S, Tuccori M, Ruggiero E, Montagnani S, Convertino I, Marino A, Fornai M, Antonioli L, Corona T, Garibaldi D, Blandizzi C. Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. *Drug Saf*. 2015; 38(10): 869-88.
20. Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. *Clin Pharmacokinet*. 2015; 54(11): 1107-23.